Seres Therapeutics (MCRB) Earnings Date, Estimates & Call Transcripts $0.59 0.00 (0.00%) (As of 11/14/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Seres Therapeutics Latest Earnings SummaryLatest Q2 2024 Earnings DateAug. 13ConfirmedActual EPS (Aug. 13) -$0.22 Beat By $0.08 Consensus EPS (Aug. 13) -$0.30 Seres Therapeutics posted Q2 2024 earnings on August 13, 2024, reporting an EPS of -$0.22, which topped analysts' consensus estimates of -$0.30 by $0.08. With a trailing EPS of -$1.18, Seres Therapeutics' earnings are expected to grow next year, from ($0.92) to ($0.59) per share. Conference Call TranscriptConference Call AudioEarnings Press Release Get Seres Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataMCRB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MCRB Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Seres Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.37-$0.37-$0.37Q2 20241-$0.36-$0.36-$0.36Q3 20241-$0.35-$0.35-$0.35Q4 20241-$0.34-$0.34-$0.34FY 20244($1.42)($1.42)($1.42) Seres Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/13/2024Q2 2024-$0.30-$0.22+$0.08-$0.22-- 5/8/2024Q1 2024-$0.36-$0.27+$0.09-$0.27-- 3/5/2024Q4 2023-$0.40-$0.32+$0.08-$0.32$0.50M$0.06M 11/2/2023Q3 2023-$0.47-$0.37+$0.10-$0.37$1.75M$0.31M 8/8/2023Q2 2023$0.55$0.36 -$0.19$0.36$125.67M$126.50M 5/9/2023Q1 2023-$0.57-$0.57--$0.57$1.58M-$0.52M Get the Latest News and Ratings for MCRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/7/2023Q4 2022-$0.41-$0.54 -$0.13-$0.54$9.04M$0.98M Seres Therapeutics Earnings - Frequently Asked Questions When did Seres Therapeutics announce their last quarterly earnings? Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earning data on Tuesday, August 13, 2024. Learn more on MCRB's earnings history. Did Seres Therapeutics beat their earnings estimates last quarter? In the previous quarter, Seres Therapeutics (NASDAQ:MCRB) reported ($0.22) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.30) by $0.08. Learn more on analysts' earnings estimate vs. MCRB's actual earnings. How can I listen to Seres Therapeutics's earnings conference call? The conference call for Seres Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Seres Therapeutics's conference call transcript? The conference call transcript for Seres Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Seres Therapeutics generate each year? Seres Therapeutics (NASDAQ:MCRB) has a recorded annual revenue of $126.32 million. How much profit does Seres Therapeutics generate each year? Seres Therapeutics (NASDAQ:MCRB) has a recorded net income of -$113.72 million. MCRB has generated -$1.18 earnings per share over the last four quarters. What is Seres Therapeutics's EPS forecast for next year? Seres Therapeutics's earnings are expected to grow from ($0.92) per share to ($0.59) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies FibroGen Earnings Results Nektar Therapeutics Earnings Results Terns Pharmaceuticals Earnings Results Aquestive Therapeutics Earnings Results ChromaDex Earnings Results KalVista Pharmaceuticals Earnings Results Contineum Therapeutics Earnings Results Ginkgo Bioworks Earnings Results Zevra Therapeutics Earnings Results Amylyx Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run The next assassination attempt won’t be on Trump (Ad)President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. This page (NASDAQ:MCRB) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MCRB Stock Alerts